Genotype-based clinical decision making in MPN
ESH eLearning, Francesco Passamonti, 174297
Implications of patient genome on clinical decision making in MDS/MPN
ESH eLearning, Michaela Fontenay, 174306
Personalized transplantation procedures in myeloid malignancies
ESH eLearning, Matteo Della Porta, 174307
Treating anaemia according to patient genome
ESH eLearning, Eva Hellström- Lindberg, 174308
ABCs of genomics
ESH eLearning, Nick Cross, 174287
Genomic applications in the clinic: are we ready?
ESH eLearning, Andreas Hochhaus, 174288
Next generation sequencing data analysis: critical issues
ESH eLearning, Torsten Haferlach, 174289
Translational implications of the medical genomics in AML
ESH eLearning, Torsten Haferlach, 174292
Genotype-tailored therapy of AML
ESH eLearning, Hartmut Döhner, 174293
Towards personalized medicine in AML
ESH eLearning, Bob Löwenberg, 174294
Precision medicine in AML: hope, hype or both?
ESH eLearning, Robert Gale, 174295
ESH eLearning, Wolfram Klapper, 173818
Elderly patient, first line
ESH eLearning, Simon Rule, 173819
Salvage treatment
ESH eLearning, Martin Dreyling, 173820
Transformed lymphoma
ESH eLearning, Wolfram Klapper, 173809
Salvage therapies
ESH eLearning, Michael Pfreundschuh, 173810
Burkitt lymphoma
ESH eLearning, Vincent Ribrag, 173811
Double hit lymphoma
ESH eLearning, Hervé TILLY, 173812
Plasmoblastic lymphoma
ESH eLearning, Miguel A Piris, 173813
CNS lymphoma
ESH eLearning, Andrés Ferreri, 173814
ESH eLearning, Philippe Gaulard, 173815
Young patient, first line
ESH eLearning, F D'Amore, 173816
Elderly patient, first line
ESH eLearning, Lorenz Trümper, 173817
Pathology ABC-GCB
ESH eLearning, Philippe Gaulard, 173803
Optimized immunotherapy
ESH eLearning, Umberto Vitolo, 173804
R-CHOP + targeted therapy
ESH eLearning, Andrew Davies, 173805
R-CHOP and maintenance
ESH eLearning, Catherine Thieblemont, 173806
Debate: In DLBCL, is cell of origin ready for prime time ?
ESH eLearning, Michael Pfreundschuh, 173807
Role of PET
ESH eLearning, Olivier CASASNOVAS, 173808
Overcoming painful bone disease in myeloma
ESH eLearning, Nicola Giuliani, 166031
History and progress of CD38 in myeloma
ESH eLearning, Fabio Malavasi, 166032
Maintenance therapy in young myeloma patients beneficial after autologous stem cell transplant
ESH eLearning, M Mohty, 166033
Better doctor-patient communication needed to improve myeloma outcomes
ESH eLearning, Karthik Ramasamy, 166034
History of antiangiogenic drugs in multiple myeloma, starting with thalidomide
ESH eLearning, Jens Hillengaß, 166035
Elderly patients should be treated based on biological age, not chronological
ESH eLearning, Heinz Ludwig, 166036
Cancer or amyloidosis?
ESH eLearning, Giovanni Palladini, 166037
Monoclonal antibodies in multiple myeloma
ESH eLearning, Phillippe Moreau, 166038
How can we make the best decisions for health whilst considering cost?
ESH eLearning, Andrea Manca, 166039
Preemptively treating patients most at risk of progression to myeloma
ESH eLearning, María-Victoria Mateos, 166040
Drug combos with daratumumab likely to become standard of care in myeloma
ESH eLearning, Niels Van De Donk, 166041
Overview of the CD38 antibody in multiple myeloma
ESH eLearning, Torben Plesner, 166042
New drugs and combinations in haematological cancers improve complete remission rates
ESH eLearning, Paolo Corradini, 166043
Benefits and problems of allogeneic stem cell transplantation as multiple myeloma treatment
ESH eLearning, Nicolaus Kröger, 166044
Causes of myeloproliferative disorders
ESH eLearning, Mary-Frances McMullin, 165429
The genomic basis of acute lymphoblastic leukaemia
ESH eLearning, Charles Mullighan, 165430
The genomics of MPNs
ESH eLearning, Peter Campbell, 165431
Epigenetic alterations and therapeutic targeting in MPN
ESH eLearning, Ross Levine, 165432
Role of megakaryocytes in the MPNs
ESH eLearning, John Crispino, 165433
Molecular insights into regulation of JAK2 in MPN
ESH eLearning, Olli Silvennoinen, 165434
Targeting JAK2 – Have we arrived?
ESH eLearning, Thomas Radimerski, 165435
Cellular and molecular response to interferon therapy in PV and ET
ESH eLearning, Josef Prchal, 165436
Modeling predisposition to familial MPN
ESH eLearning, Isabelle Plo, 165437
Using single cell biology to identify stem cell fate regulators in haematological malignancies
ESH eLearning, David Kent, 165438
The effects of specialized microenvironments on haematopoiesis in myelofibrosis
ESH eLearning, Ronald Hoffman, 165439
Natural history and risk stratification of prefibrotic myelofibrosis
ESH eLearning, Giovanni Barosi, 165440
Rethinking the treatment recommendations in low-risk PV
ESH eLearning, Tiziano Barbui, 165441
Next generation MPN management
ESH eLearning, Ruben Mesa, 165442
Cytogenetics and NGS
ESH eLearning, Hervé Avet-Loiseau, 165480
Minimal residual disease
ESH eLearning, Bruno Paiva, 165481
Bone disease
ESH eLearning, Nicola Giuliani, 165482
ESH eLearning, Nikhil Munshi, 165483
ESH eLearning, Fabio Malavasi, 165484
Signalling pathways
ESH eLearning, Tuna Mutis, 165485
When to treat
ESH eLearning, Sonja Zweegman, 165486
ESH eLearning, Elena Zamagni, 165487
MGUS and smoldering myeloma
ESH eLearning, María-Victoria Mateos, 165488
Drug development in myeloma
ESH eLearning, Sagar LONIAL, 165489
ESH eLearning, Hermann Einsele, 165490
ESH eLearning, Michele Cavo, 165491
Front line therapy for frail patients
ESH eLearning, Alessandra Larocca, 165492
Supportive care
ESH eLearning, Heinz Ludwig, 165493
Monoclonal antibodies
ESH eLearning, Torben Plesner, 165494
How to sequence agents in RRMM
ESH eLearning, Philippe Moreau, 165495
ESH eLearning, Steven Treon, 165496
ESH eLearning, Giampaolo MERLINI, 165497
Inducing non-cell autonomous killing of double-hit lymphoma
ESH eLearning, David Weinstock, 165449
Integration of genetic and clinical information into one score, the CLL-IPI project
ESH eLearning, Jasmin Bahlo, 165450
Functional interactions between malignant and non-malignant cells in lymphoma
ESH eLearning, Hans-Guido Wendel, 165451
Drugs targeting the TME of Hodgkin lymphoma: the clinical story of Nivolumab and other PD1/PDL1 inhibitor
ESH eLearning, Peter Borchmann, 165452
Genomic profiling and clonal evolution under treatment of CLL lymphoma
ESH eLearning, Catherine Wu, 165453
ESH eLearning, Christoph Plass, 165454
PET and CT imaging in Hodgkin lymphoma
ESH eLearning, Lena Specht, 165455
Imaging and circulating tumour DNA in lymphoma
ESH eLearning, Wyndham Wilson, 165456
History and future role of immune therapy in lymphoma
ESH eLearning, Ronald Levy, 165457
Allogeneic stem cell transplantation for lymphoid malignancies – coming to an end?
ESH eLearning, David MALONEY, 165458
Mechanisms of BCL2 inhibitors
ESH eLearning, Anthony Letai, 165459
Development of targeted agents in ALL
ESH eLearning, Charles Mullighan, 165460
New agents in the management of NHL
ESH eLearning, Gilles Salles, 165461
The US trials on NHL
ESH eLearning, Richard Little, 165462
The GCLLSG trials
ESH eLearning, Michael Hallek, 165463
The UK trials on CLL
ESH eLearning, Peter Hillmen, 165464
Treatment of paediatric lymphoma
ESH eLearning, Catherine Patte, 165465
Treatment of CNS lymphoma
ESH eLearning, Andres Ferreri, 165466
Treatment of Waldenström macroglobulinemia
ESH eLearning, Steven Treon, 165467
EHA research roadmap for lymphoma
ESH eLearning, Gilles Salles, 165468
Tools for the analysis of big data
ESH eLearning, Clemens Suter-Crazzolara, 165469
The expectations of American patients
ESH eLearning, Brian Koffman, 165470
The expectations of European patients
ESH eLearning, Karen Van Rassel, 165471
Early non-infectious complications
ESH eLearning, Enric Carreras, 165978
Chronic GVHD
ESH eLearning, Tamas Masszi, 165994

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Save Settings